NASDAQ: SILO - Silo Pharma, Inc.

Rentabilité sur six mois: -0.5291%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Silo Pharma, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Silo Pharma, Inc.

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders.

plus de détails
The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2014-05-13
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://silopharma.com
Цена ао 1.94
Changement de prix par jour: -1.16% (0.951)
Changement de prix par semaine: +7.06% (0.878)
Changement de prix par mois: +4.44% (0.9)
Changement de prix sur 3 mois: -13.76% (1.09)
Changement de prix sur six mois: -0.5291% (0.945)
Changement de prix par an: -34.72% (1.44)
Evolution du prix sur 3 ans: +487.5% (0.16)
Evolution du prix sur 5 ans: +12 602.7% (0.0074)
Evolution des prix sur 10 ans: 0% (0.94)
Evolution des prix depuis le début de l'année: -18.26% (1.15)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 68.34 1
P/BV 0.7978 9
P/E 0 0
EV/EBITDA -0.364 0
Total: 4.63

Efficacité

Nom Signification Grade
ROA, % -47.77 0
ROE, % -59.91 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 75.86 8
Rentabilité Ebitda, % 327.45 10
Rentabilité EPS, % -46.12 0
Total: 7.6
Plus de détails

Établissements Volume Partager, %
Financial Advocates Investment Management 62807 0.06
UBS Group AG 32843 0.03
Vanguard Group Inc 16334 0.02
Geode Capital Management, LLC 16179 0.02
TWO SIGMA SECURITIES, LLC 12788 0.01
State Street Corporation 12500 0.01
Tower Research Capital LLC (TRC) 7007 0.01
Westside Investment Management, Inc. 94 0
FWL INVESTMENT MANAGEMENT, LLC 80 0
Wells Fargo & Company 20 0

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
SPDR S&P Emerging Markets Small Cap ETF 0.01392 5.46 3.03583
Dimensional Emerging Markets Core Equity 2 ETF 0.00246 15.96 3.34087
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.00179 12.46 3.59676
Dimensional Emerging Markets Value ETF 0.00004 17.07 4.19508
Avantis Emerging Markets Equity ETF 0.00003 8.77 3.60513



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Eric Weisblum Chairman, President & CEO 569.01k 1970 (55 années)
Mr. Daniel E. Ryweck Chief Financial Officer 62.69k 1965 (60 années)
Dr. James S. Kuo M.B.A., M.D. Vice President of Research & Development N/A 1965 (60 années)

Adresse: United States, Englewood Cliffs. NJ, 560 Sylvan Avenue - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://silopharma.com